Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 inf...

Full description

Bibliographic Details
Main Authors: Donald M. Jensen, Tarik Asselah, Douglas Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M. Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E. Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W. Paik, David K. Wong, Edward Tam, Kelly Kaita, S. Victor Feinman, Jerry O. Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O. Böcher, Peter Ferenci
Format: Article
Language:English
Published: Elsevier 2016-05-01
Series:Annals of Hepatology
Subjects:
Hepatitis C
Viral hepatitis
Direct-acting antiviral
SVR12
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119306520

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119306520

Similar Items